Announcement PDF Appendix 3Z Final Director’s Interest Notice Appendix 3Z Rule 3.19A.3 Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Invion Limited ABN 76 094 730 417 We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of director Greg Collier Date of last notice 4 November 2019 Date that director ceased to be director 4 November 2019 Part 1 – Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Number & class of securities N/A + See chapter 19 for defined terms. 11/3/2002 Appendix 3Z Page 1 Appendix 3Z Final Director’s Interest Notice Part 2 – Director’s relevant interests in securities of which the director is not the registered holder Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Name of holder & nature of interest Number & class of securities Note: Provide details of the circumstances giving rise to the relevant interest Indirect holdings are Beacon Super Fund Pty Ltd ATF Beacon Super Fund of which Dr Collier is a director and beneficiary; Barwon Biotechnology Pty Ltd of which Dr Collier is a director and shareholder; and Fusion Biosciences Pty Ltd of which Dr Collier is a director. 28,770,932 fully paid ordinary shares (indirectly held). 136,288,073 Share options exercisable at $0.03 each on or before 12 February 2023 (IVXAT). Part 3 – Director’s interests in contracts Detail of contract N/A Nature of interest Name of registered holder (if issued securities) No. and class of securities to which interest relates + See chapter 19 for defined terms. Appendix 3Z Page 2 11/3/2002